Log in

American Osteopathic Association's Annual Osteopathic Medical Conference and Exposition (OMED) is the premier educational event for the osteopathic medical profession.

Register Now!
Use this registration code for $100 off: DOPROUD22

AOAAM’s Agenda at OMED 2022

October 27 – October 30, 2022 Live in Boston, MA
Also available virtually.

The American Osteopathic Academy of Addiction Medicine (AOAAM) is offering 15 hours of CME at OMED 2022. The program will include a four-hour DATA 2000 Waiver Training utilizing new materials developed within the Providers Clinical Support System (PCSS). Educational sessions will inform the practicing osteopathic physician on recent changes to national practice guidelines, improve clinicians’ ability to treat co-occurring mental health disorders, and thoughtfully examine the changing landscape of addiction medicine. The AOAAM will provide this content live in-person and virtual.

Thursday, 10/27/2022 - 1:00 PM - 5:00 PM
The Office-Based Treatment for Opioid Use Disorders -Waiver Eligibility Training Part 1  – 4 CME

Stephen Wyatt, DO, FAOAAM & William Morrone, DO, FAOAAM

The Drug Addiction Treatment Act of 2000 (DATA 2000), the Comprehensive Addiction and Recovery Act (CARA) and the Substance Use-Disorder Prevention Opioid Recovery and Treatment for Patients and Communities (SUPPORT) Act allows qualified practitioners to dispense or prescribe buprenorphine for the treatment of opioid use disorders (OUD) in settings other than opioid treatment programs (OTP), upon completion of specialized training.

To receive a practitioner waiver to administer, dispense, and prescribe buprenorphine, practitioners must notify SAMHSA’s Center for Substance Abuse Treatment (CSAT), Division of Pharmacologic Therapies (DPT) of their intent to practice this form of medication-assisted treatment (MAT). Qualified practitioners include physicians, Nurse Practitioners (NPs), Physician Assistants (PAs), Clinical Nurse Specialists (CNSs), Certified Registered Nurse Anesthetist (CRNAs), and Certified Nurse-Midwives (CNMs).

Physicians are required to apply to the Drug Enforcement Agency for a waiver to prescribe buprenorphine, one of three medications approved by the FDA for the treatment of opioid use disorder. Those physicians who want to treat more than 30 patients at any one time, must take the 8-hour waiver course

To treat more than 30 patients, Advanced Practice Registered Nurses (APRN) (NP/CNM/CNS/CRNA) and Physician Assistants (PAs) must complete 24 hours of specialized training to prescribe buprenorphine. The training includes 8 hours of waiver training and an additional 16 hours of training

Students can take the course during their educational program and apply for their waiver when they obtain their full DEA license. The course certificate of completion does not expire.

The 1st half of the training is a 4.25-hour live training. The 2nd half of the course is a 3.75-hour on-your-own online study. An exam on Part 2 must be completed within 30 days of the webinar session.

Learning Objectives - Participants will be able to:

1) To understand the federal Drug Abuse Treatment Act (DATA) of 2000 and the subsequent revisions that lists the criteria needed for Office-Based Opioid Treatment (OBOT) utilizing buprenorphine for opioid dependence and the new changes/guidelines.

2) To distinguish between spontaneous withdrawal and precipitated withdrawal and the appropriate methods of buprenorphine induction.

3) To describe and contrast the functions of full mu agonists, partial agonists and antagonists.

4) To describe the basic approach used in at least three different types of non-pharmacological treatment of opioid dependence.

5) To describe three symptoms of opioid withdrawal or intoxication that mimic symptoms of a psychiatric disorder.

6) To list the criteria for establishing the diagnosis of opioid dependence.

7) To describe at least three factors to consider in determining if the patient is an appropriate candidate for office-based treatment with buprenorphine.

8) To describe at least three areas that should be covered in the rules and expectations that are communicated to patients during the patient assessment process.

9) To list at least three situations in which patient information, with patient identity, can be shared under current laws protecting the patient’s confidentiality.

10) To understand and minimize buprenorphine misuse and diversion. To be aware of the issues of drug interactions of buprenorphine and pediatric exposures.

Friday, 10/28/2022 - 9:30 AM - 10:30 AM 
Updates from ASAM Clinical Practice Guideline on Alcohol Withdrawal Management – 2020 – 1 CME
Julie Kmiec, DO, FAOAAM

During this lecture, the newest ASAM guidelines for the treatment of alcohol withdrawal will be reviewed, including withdrawal management in both the inpatient and outpatient settings, according to the latest edition of the ASAM guidelines.

Learning Objectives - Participants will be able to:

1) Describe how to screen for unhealthy alcohol use and diagnose alcohol use disorder and alcohol withdrawal

2) Assess for risk factors for severe or complicated withdrawal

3) Assess for appropriateness of inpatient versus outpatient withdrawal management

4) Discuss pharmacotherapy options for differing severities of alcohol withdrawal

Friday, 10/28/2022 - 10:30 AM - 11:30 AM        
Update on Opioid Use Disorder Practice Guidelines – 1 CME
Stephen Wyatt, DO, FAOAAM

This presentation will review updates in the epidemiology of opioid use disorders, recent regulatory changes, and their effect on clinical practice. There will be material on recent research comparing buprenorphine and extended-release naltrexone, new formulations of buprenorphine, and changing buprenorphine initiation protocols in the age of fentanyl.

Learning Objectives - Participants will be able to:

1) Explain the evolving problems associated with opioid use disorders in the past few years.

2) Describe regulatory changes relevant to the treatment of opioid use disorders.

3) Describe changing standards of care in the use of buprenorphine in the age of fentanyl.

4) Describe updates in treating patients with opioid use disorders and concurrent pain and pregnancy. 

Friday, 10/28/2022 - 11:30 AM - 12:30 PM         
Journal of Addictive Diseases – 1 CME
R. Gregory Lande, DO, FAOAAM

The presentation will provide instructions for authors interested in submitting a manuscript, guidance for peer reviewers, and discuss a selection of articles published in the Journal

Learning Objectives - Participants will be able to:

1) Physicians will learn the basics of how they can submit a manuscript.

2) Physicians will learn about peer review and how they can become a reviewer.

3) Attendees will learn about a selection of articles published in the Journal with a focus on those that address clinical practice in addiction medicine.

Friday, 10/28/2022 - 12:30 PM - 1:30 PM           

Friday, 10/28/2022 - 1:30 PM - 2:30 PM
The Addiction Medicine Mentorship Program (AMMP):  An Innovative Model for Medical Student Addiction Education – 1 CME
James Latronica, DO, R. Gregory Lande, DO, FAOAAM, Sanisha Balsara, & Monisha Amin

The Addiction Medicine Mentorship Program (AMMP) is a novel, longitudinal learning program for medical students to learn the science of addiction through the framework of academic and policy literature.

Learning Objectives - Participants will be able to:

1) Discuss the state of addiction curricula in U.S. medical schools

2) Discuss the structure and function of the AMMP

3) Have two representative students share their experience with the program as well as their research project

Friday, 10/28/2022 - 2:30 PM - 3:30 PM
Withdrawal Management in Correctional Settings – 1 CME
Jon Lepley, DO

A disproportionate number of people in jails and prisons have a substance use disorder. Healthcare providers who work in these settings have an opportunity to identify and treat substance withdrawal. This lecture will provide an overview of the demographics of incarcerated people in the United States and describe the general framework for provision of healthcare within correctional institutions. Specific practical guidance for recognizing and treating substance withdrawal will be provided.

Learning Objectives - Participants will be able to:

  1. Understand the demographics of incarcerated people and prevalence of substance use disorders in correctional environments
  2. Understand and be familiar with delivery of health care services in correctional settings
  3. Describe some practical considerations when treating substance withdrawal in correctional settings

Friday, 10/28/2022 - 3:30 PM - 4:30 PM
SUD and Co-Occurring Mood and Anxiety Disorders – 1 CME
Mitch Crawford, DO

The session will focus on the exploration of common mood and anxiety disorders, in the setting of comorbid substance use disorder.  The presentation will be interactive, with participation requested from the audience with the hopes of stimulating thought-provoking dialogue.

Learning Objectives - Participants will be able to:

1) List criteria for common mood disorders.

2) Identify criteria for common mood disorders.

3) Describe special consideration for treatment of substance use disorders in the setting of comorbid mood or anxiety disorders.

Friday, 10/28/2022 - 6:30 PM - 9:00 PM
AOAAM Board of Trustee Meeting - Current Board and Past Presidents

Saturday, 10/29/2022 - 9:30 AM - 10:30 AM      
Outliers: A History of Health Insurance in the United States – 1 CME
James Latronica, DO

The mixture of public and private health insurance in the United States has long been the ""default"" paradigm for how Americans pay for health care, but the United States is an outlier in how it pays for health care compared to other wealthy nations. So, how did we get here?

In this talk, we will discuss the history of health insurance in the United States, the medical, legal, and political influences that have shaped this history, and the ultimate results of these various influential forces. Even for physicians and other allied health care practitioners who are intimately aware of the functional, modern workings of insurance in the United States, the run-up to our current model will likely be unfamiliar and eye-opening.

Learning Objectives - Participants will be able to:

  1. Discuss the history of health insurance in the United States
  2. Discuss medico-legal and political influences that have shaped health policy
  3. Compare/contrast health insurance models and outcomes in “peer countries”

Saturday, 10/29/2022 - 10:30 AM - 11:30 AM    
Clinical, Legal and Ethical Considerations when Treating SUD – 1 CME
William Morrone, DO, FAOAAM

Discussion of the multifaceted information needed when embarking on the treatment of patients with SUD from a self-preservation standpoint in areas such as legal ramifications, ethical dilemmas, and clinical assessment.

Learning Objectives - Participants will be able to:

1) Examine the core principles of opioid use disorder treatment through the chronic disease framework of addiction.

2) Explore safe buprenorphine prescribing recommendations, guidance, and implementation strategies for new prescribers to conform with legal standards.

3) Identify best practices and clinical considerations for buprenorphine initiation, stabilization, dosing, treatment, and discontinuation.

4) Examine recommendations for ongoing patient management, monitoring, engagement, and care.

Saturday, 10/29/2022 - 11:30 AM - 12:30 PM    
Low Barrier Buprenorphine Treatment – 1 CME
Margaret Lowenstein, MD

Low-barrier or low-threshold treatment is an emerging philosophy of care that incorporates concepts like flexible, same-day treatment with medication for OUD (MOUDs) and a harm reduction approach to increase access for those poorly served by traditional care delivery models. Although there is no standard blueprint, low-barrier programs typically take a “medication first” approach, providing MOUDs, particularly buprenorphine in a way that focuses on rapid access, limiting unnecessary requirements, and incorporating a harm reduction approach. This lecture will cover key concepts and evidence supporting the implementation of low-barrier treatment as well as examples of low-barrier treatment in action and practical strategies for incorporating these principles into your practice.

Learning Objectives - Participants will be able to:

1) Describe key principles of low-barrier buprenorphine care.

2) Understand the evidence supporting a "medication first" approach to OUD care.

3) Identify ways of applying low-barrier principles in your practice.

Saturday, 10/29/2022 - 12:30 PM - 1:30 PM      

Saturday, 10/29/2022 - 1:30 PM - 2:30 PM        
Harm Reduction – 1 CME
Margaret Lowenstein, MD

In this lecture, we will discuss the principles underlying harm reduction as well as practical strategies that clinicians can use to counsel patients to increase safety and reduce drug-related harms. These include naloxone provision, strategies for safer use, syringe service programs, and fentanyl test strips. The talk will also provide attendees with resources to identify state and local regulations and harm reduction service providers.

Learning Objectives - Participants will be able to:

1) Describe key harm reduction principles

2) Discuss specific strategies to reduce substance-related harm with patients in your practice

3) Identify state or local harm reduction resources

Saturday, 10/29/2022 - 2:30 PM - 3:30 PM        
Panel Discussion - The Evolution of Addiction Treatment during COVID-19 – 1 CME
Morrone, DO, FAOAAM, Kmiec, DO, FAOAAM, Crawford, DO - Lepley, DO, FAOAAM (Moderator)

Public health recommendations during the COVID-19 pandemic forced addiction treatment providers to find innovative ways to continue to provide patient care. Regulations generally allowed for a lower threshold approach to initiating and maintaining some medications for opioid use disorder. The calculus on risks and benefits of residential treatment needed to be viewed in the context of the pandemic. Many of these adaptations persist to this day. Additionally, the unprecedented increase in overdose deaths during the pandemic has fostered a focus on Harm Reduction as part of addiction treatment

As physical distancing recommendations recede, addiction treatment providers must decide which adaptations to the pandemic are genuine innovations worthy of continued utilization and which adaptations no longer have relevance or valid clinical utility. This panel will discuss the future landscape of addiction treatment based on experiences providing care during the COVID-19 pandemic.

Learning Objectives - Participants will be able to:

1) Understand changes in regulation that allowed for lower barrier access to MOUD and discuss the advantages and disadvantages of these changes.

2) Recognize 'Harm Reduction' as practical strategies for reducing drug overdose deaths and consider which overdose prevention strategies can be implemented in traditional addiction treatment settings

3) Discuss the role of residential treatment settings and how panelists viewpoints may have changed during the COVID-19 pandemic.

Saturday, 10/29/2022 - 3:30 PM - 4:00 PM        
Cookies and Conversations with the Experts

Saturday, 10/29/2022 - 4:00 PM - 5:00 PM        
AOAAM Annual Meeting


Non-members interested in CME must create a profile with AOAAM. Subscribe now or Join Us to receive the full benefits of membership.

Latest News  read more

The mission of the American Osteopathic Academy of Addiction Medicine is to improve the health of individuals and families burdened with the disease of addiction.

Powered by Wild Apricot Membership Software